The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative Sciences & eXtellia, and his teams shared their scientific expertise in CRISPR/Cas9 technology and clinical development experience to the members in Corn lab.
Cian received his PhD in Brain and Cognitive Sciences from MIT in January 2026. In July 2026, he joined the Corn lab as a postdoctoral researcher. His research...
Genome editing therapies often rely on viral delivery systems such as adeno-associated viruses (AAVs), which have limited cargo capacity. Although RNA-guided...
A highlight of the summer scientific calendar, the SwissPR Symposium on Genome and Transcriptome Engineering, took place on June 30, 2026, in Basel. Co-organized...
Questions and/or comments about Corn Lab and its activities may be addressed to:
